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Abstract
Plasmodium spp parasites harbor an unusual plastid organelle called the apicoplast. Due to its prokaryotic origin and
essential function, the apicoplast is a key target for development of new anti-malarials. Over 500 proteins are predicted to
localize to this organelle and several prokaryotic biochemical pathways have been annotated, yet the essential role of the
apicoplast during human infection remains a mystery. Previous work showed that treatment with fosmidomycin, an
inhibitor of non-mevalonate isoprenoid precursor biosynthesis in the apicoplast, inhibits the growth of blood-stage P.
falciparum. Herein, we demonstrate that fosmidomycin inhibition can be chemically rescued by supplementation with
isopentenyl pyrophosphate (IPP), the pathway product. Surprisingly, IPP supplementation also completely reverses death
following treatment with antibiotics that cause loss of the apicoplast. We show that antibiotic-treated parasites rescued
with IPP over multiple cycles specifically lose their apicoplast genome and fail to process or localize organelle proteins,
rendering them functionally apicoplast-minus. Despite the loss of this essential organelle, these apicoplast-minus
auxotrophs can be grown indefinitely in asexual blood stage culture but are entirely dependent on exogenous IPP for
survival. These findings indicate that isoprenoid precursor biosynthesis is the only essential function of the apicoplast
during blood-stage growth. Moreover, apicoplast-minus P. falciparum strains will be a powerful tool for further investigation
of apicoplast biology as well as drug and vaccine development.
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Introduction
The discovery of a plastid organelle, the apicoplast, in
Plasmodium spp. (responsible for 250 million cases of human
malaria each year) and other Apicomplexa parasites instantly
made it a key target in the development of new therapies against
these pathogens [1–3]. The need for new anti-malarials is
particularly urgent given the documentation of developing
resistance to the current last-line therapy in the deadliest species,
P. falciparum [4]. Several features of this organelle make it both
biologically fascinating and an attractive therapeutic target. The
apicoplast is derived from secondary endosymbiosis of a plastid-
bearing red algae and is therefore prokaryotic in origin, containing
pathways that have no counterpart in the human host [3,5,6].
During the course of evolution, the apicoplast has lost its
photosynthetic function and transferred most of its genome to
the nucleus, requiring a dedicated protein targeting pathway to
localize the majority of its over 500 gene products into the
organelle [7,8]. The remaining 35 kb apicoplast genome encodes
,50 mostly housekeeping genes, including ribosome subunits,
tRNAs, RNA polymerase, and a chaperone thought to be involved
in protein import [1]. Despite its minimalization, the apicoplast
continues to serve essential though poorly defined metabolic
function(s). In Plasmodium, apicoplast function is necessary for both
intraerythrocytic and intrahepatic development in the human host
[9,10]. Whether the apicoplast is required for sexual stage
development in the mosquito is currently unknown [11–14].
The essential role of the apicoplast has been clearly demon-
strated by the effect of antibiotics on blood-stage P. falciparum. Dahl
et al. showed that antibiotics that inhibit prokaryotic transcription
or translation, such as doxycycline, specifically blocks expression of
the apicoplast genome [9,15]. Parasites treated during first 48 h
life cycle show no obvious defect from the loss of apicoplast-
encoded gene products: Organelle morphology, genome replica-
tion, protein targeting, and segregation during cell division remain
intact. Likewise, parasites progress normally through the ring,
trophozoite, and schizont developmental stages, giving rise to
daughter merozoites that successfully reinvade to establish
infection of a new host cell. Instead, a curious ‘‘delayed death’’
phenotype is observed, whereby the deleterious effects of antibiotic
inhibition accumulate in the progeny of treated parasites. In this 2nd
life cycle following antibiotic treatment, the apicoplast genome
fails to replicate. Protein import function is lost. Finally, the
organelle itself fails to replicate and segregate during cell division.
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Because the apicoplast cannot be generated de novo and must be
inherited at each cell division, the failure of organelle replication
and segregation in these parasites results in loss of the apicoplast in
daughter cells and parasite death. Overall, antibiotic-induced
delayed death begins with specific inhibition of apicoplast
transcription and translation in one life cycle and ends with
irreversible apicoplast loss and death in the subsequent cycle. A
similar delayed death has been observed in Toxoplasma gondii
following antibiotic treatment or transgene expression that cause
apicoplast loss [16,17].
Despite its promise as Plasmodium’s ‘‘Achilles heel,’’ the function
of the apicoplast has eluded researchers in the nearly 20 years
since its discovery. Without knowledge of specific proteins or
pathways suitable as drug targets, particularly during the clinically
symptomatic blood stage, efforts to develop apicoplast-directed
therapies (beyond known antibiotics) have been stymied. An
astounding 5%–10% of the nuclear genome is predicted to contain
an apicoplast targeting signal, yet 70% of these apicoplast gene
products are of unknown function [18–20]. Pathways that have
been identified include those for the biosynthesis of isoprenoid
precursors, fatty acids, heme, Fe-S clusters, and lipoic acid [21].
While in silico analysis has been revealing, many pathways will go
undetected and the essentiality of predicted pathways throughout
the parasite’s complex life cycle needs to be experimentally
validated. For example, inhibition by the antibiotic triclosan
initially suggested that apicoplast-located type II fatty acid
biosynthesis was essential in blood-stage parasites, prompting the
development of fatty acid inhibitors as anti-malarials [22]. Later,
genetic deletion of fatty acid biosynthetic genes definitively proved
that this pathway is not required for blood stage growth and
instead is critical for liver stage development [23,24]. Unfortu-
nately, discovery and validation of apicoplast pathways has been
hampered by the limited ability to generate knockouts of essential
genes, isolate the organelle, or purify Plasmodial proteins for in
vitro characterization [25–28].
Amongst the annotated apicoplast pathways, Plasmodium relies
on the prokaryotic MEP/DOXP/non-mevalonate pathway for
synthesizing isoprenoid precursors rather than the canonical
mevalonate pathway used by most other eukaryotes and all
mammals (including the human host) [29,30]. Both pathways
produce isopentenyl pyrophosphate (IPP) and dimethylallyl
pyrophosphate (DMAPP) as the final products, but the enzymes
and chemical intermediates leading to synthesis of these
compounds are entirely different. Fosmidomycin, an inhibitor of
the MEP pathway, kills blood-stage parasites and has been tested
in clinical trials as an antimalarial [31,32]. Inhibition by
fosmidomycin suggests that isoprenoid precursor biosynthesis is
essential in blood-stage infection, although the possibility of off-
pathway targets as the cause of the drug effect (as was found to be
the case for triclosan) has not been ruled out [29,33]. Furthermore,
IPP and DMAPP are not an end onto themselves but rather
building blocks used to synthesize small molecule isoprenoids with
a host of functions or C15/C20 prenyl chains for the post-
translational modification of proteins [34,35]. Once IPP and
DMAPP are exported into the parasite cytoplasm, the downstream
isoprenoid products in Plasmodium and their function during
infection are unknown.
The significance of isoprenoid precursor biosynthesis as a drug
target and gateway for identifying isoprenoid products with
essential functions in pathogenesis depends on a clear demonstra-
tion of its role in parasite survival. In addition to its essentiality,
this pathway may represent the only direct output from the
apicoplast into the cytoplasm during blood stage growth since the
remaining annotated pathways function primarily for organelle
maintenance, support the mitochondria, or are not essential in this
stage. Given the difficulty of studying the apicoplast by traditional
methods, we employed an alternative strategy using drug
inhibition/chemical rescue, equivalent to genetic deletion/com-
plementation, to establish pathway essentiality and sufficiency.
Using this simple chemical genetic approach, we show that
isoprenoid precursor biosynthesis is not only essential but in fact
the sole essential function of the apicoplast during blood-stage
growth.
Results
Isoprenoid Precursors Chemically Rescue Fosmidomycin
Inhibition
To investigate the specificity of fosmidomycin for the isoprenoid
precursor biosynthetic pathway, we observed the effect of
supplementation with isoprenoid precursors, IPP and DMAPP,
on drug inhibition of blood-stage parasites. Growth inhibition
of blood-stage P. falciparum W2 by fosmidomycin occurred with
an EC50 = 0.98 mM (95% confidence interval = 0.93–1.03 mM;
Figure 1A). When drug susceptibility was performed in media
supplemented with 200 mM IPP, DMAPP, or both IPP and
DMAPP, only IPP (without DMAPP) was sufficient to completely
reverse the growth inhibition in the presence of up to 100 mM
fosmidomycin (Figure 1A). Survival of parasites was dependent on
the concentration of IPP in the media with rescue apparent at
200 mM IPP (Figure 1B). DMAPP alone or in combination with
IPP had no effect or was even slightly toxic (Figure 1A). Addition
of up to 2 mM 3-methyl-3-butenol, the alcohol analog of IPP
lacking the pyrophosphate moiety, alone or in combination with 3-
methyl-2-butenol, the alcohol analog of DMAPP, also did not
rescue fosmidomycin inhibition (Figure S1). Finally, reversal of
drug inhibition by addition of IPP was only seen with
fosmidomycin and did not occur with chloroquine, a drug that
does not target isoprenoid precursor biosynthesis (Figure S2).
Author Summary
Malaria caused by Plasmodium spp parasites is a profound
human health problem that has shaped our evolutionary
past and continues to influence modern day with a disease
burden that disproportionately affects the world’s poorest
and youngest. New anti-malarials are desperately needed in
the face of existing or emerging drug resistance to available
therapies, while an effective vaccine remains elusive. A
plastid organelle, the apicoplast, has been hailed as
Plasmodium’s ‘‘Achilles’ heel’’ because it contains bacteria-
derived pathways that have no counterpart in the human
host and therefore may be ideal drug targets. However,
more than a decade after its discovery, the essential
functions of the apicoplast remain a mystery, and without
a specific pathway or function to target, development of
drugs against the apicoplast has been stymied. In this study,
we use a simple chemical method to generate parasites that
have lost their apicoplast, normally a deadly event, but
which survive—‘‘rescued’’ by the addition of an essential
metabolite to the culture. This chemical rescue demon-
strates that the apicoplast serves only a single essential
function, namely isoprenoid precursor biosynthesis during
blood-stage growth, validating this metabolic function as a
viable drug target. Moreover, the apicoplast-minus Plasmo-
dium strains generated in this study will be a powerful tool
for identifying apicoplast-targeted drugs and as a potential
vaccine strain with significant advantages over current
vaccine technologies.
Chemical Rescue of Apicoplast-Minus P. falciparum
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These findings establish that (1) fosmidomycin inhibition is specific
for the isoprenoid precursor biosynthetic pathway, (2) isoprenoid
precursor biosynthesis is essential for blood-stage P. falciparum, and
(3) exogenous IPP fulfills endogenous biosynthetic function.
IPP Supplementation Rescues Antibiotic-Induced
Delayed Death
To determine whether rescue of the isoprenoid precursor
biosynthesis pathway can reverse delayed death due to antibiotics,
P. falciparum W2 parasites were treated with chloramphenicol,
clindamycin, or doxycycline in the presence of IPP. As described
above, treatment of blood-stage parasites with these prokaryotic
transcription and translation inhibitors specifically blocks apico-
plast gene expression in the first 48 h cycle leading to apicoplast
loss and parasite death in the second cycle [9,15]. As such,
antibiotic treatment yielded a 48 h EC50 in growth assays due to
nonspecific inhibition and a lower 96 h EC50 due to apicoplast-
specific inhibition (Table 1). This shift in the EC50 values from 48
to 96 h is characteristic of the delayed death phenotype. By
supplementing with 200 mM IPP, reversal of apicoplast-specific
inhibition at 96 h by all drugs was observed with EC50 values
reflective of only nonspecific drug effects. In fact, when addition of
IPP was compared from 48–96 h or 0–96 h, IPP was only
required during the second cycle consistent with a deficiency in
the progeny of treated parasites (Table 1). Similar results were
demonstrated with P. falciparum D10 strain, suggesting that the
rescue of antibiotic inhibition by IPP is not strain-specific (Table 1).
Blood-stage parasites were carried through several life cycles
with simultaneous antibiotic treatment and IPP rescue to
determine (1) any significant growth defects and (2) the
dependence on further supplementation with IPP (after removal
of the antibiotic) of the surviving parasites. As shown in Figure 2A,
the doxycycline-treated, IPP-rescued strain showed parasitemia
$65% of that seen in the untreated strain throughout the
treatment/rescue course. (Given the narrow concentration range
between apicoplast-specific and nonspecific inhibition for doxy-
cycline, some decreased growth due to non-specific inhibitory
effects is expected at the drug concentration used.) Moreover, the
rescued strain was carried for a total of 26 days with IPP
supplementation but in the absence of antibiotics with no
diminishment in growth capacity. In contrast, doxycycline-
treated parasites without added IPP quickly died after the 2nd
cycle of treatment with undetectable parasitemia by the end of
the 3rd cycle (Figure 2A). Significantly, removal of IPP and
doxycycline from the media at the start of the 4th cycle results in a
rapid decline in parasitemia of the rescued parasites (Figure 2A).
Figure 1. Chemical rescue of fosmidomycin inhibition with IPP precursors. (A) Growth inhibition by fosmidomycin (0–100 mM) in media
supplemented with 200 mM IPP, DMAPP, or both IPP and DMAPP. (B) Concentration dependence of IPP rescue.
doi:10.1371/journal.pbio.1001138.g001
Table 1. Rescue of apicoplast-specific growth inhibition by antibiotics.
Strain Drug EC50 (mM)
a
48 h 96 h
No Rescue +IPP No Rescue +IPP 0–96 h +IPP 48–96 h
W2 Chloramphenicol .300b .300b 13.7 (9.7–19.4) .300b .300b
W2 Clindamycin .10b .10b 0.004 (0.002–0.006) .10b ND
W2 Doxycycline 4.9 (2.9–8.5) 5.1 (2.3–11.0) 0.3 (0.2–0.4) 3.2 (2.6–3.9) ND
D10 Chloramphenicol .300b .300b 19.8 (13.6–28.8) .300b .300b
ND, not determined.
aRepresented as mean (95% confidence interval).
b50% inhibition above highest assayed concentration.
doi:10.1371/journal.pbio.1001138.t001
Chemical Rescue of Apicoplast-Minus P. falciparum
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With further passage in media lacking both IPP and doxycycline,
the parasitemia of rescued parasites became undetectable. Again
similar results could be demonstrated with P. falciparum D10 strain
or treatment with chloramphenicol (Figures S3 and S4). These
results show that antibiotic-treated parasites rescued by IPP
supplementation have no gross growth defect but are entirely
dependent on exogenous IPP for continued growth. We cannot
rule out more subtle growth defects that would be difficult to
assess by comparison of parallel cultures.
Antibiotic-Treated, IPP-Rescued Parasites Lose Their
Apicoplast Genome
IPP rescue of death following antibiotic treatment could be
due to either (1) blocking the deleterious effects of antibiotic
treatment to cause apicoplast loss or (2) compensating for the
loss of the apicoplast. The irreversible dependence of the
rescued parasites on IPP (even after removal of the antibiotic)
suggests the latter—that apicoplast loss occurs but is chemically
complemented by exogenous IPP. We sought to confirm
whether the sequelae of apicoplast dysfunction that occurs
following treatment with antibiotics (reviewed above) also bears
out in IPP-rescued parasites [9]. A hallmark of organelle
dysfunction is the loss of the apicoplast genome [9,16]. We used
quantitative PCR for target genes on the apicoplast, mitochon-
dria, and nuclear genomes to monitor the ratio of organelle:
nuclear genomes during the course of antibiotic treatment and
chemical rescue. Figure 2B demonstrates a marked decline in
the apicoplast:nuclear genome ratio after the 2nd cycle in all
antibiotic-treated parasites regardless of supplementation with
IPP. At the end of the 4th cycle, the ratio is reduced by at least
100-fold. In contrast, no such decline is noted in the
mitochondria:nuclear genome ratio (Figure 2C). Rescued strains
carried out for a total of 26 days continued to show undetectable
apicoplast genome and detectable mitochondria and nuclear
genomes. Thus, IPP-rescued parasites undergo a specific and
irreversible loss of the apicoplast genome without concomitant
loss of the nuclear or mitochondrial genomes, yet these parasites
continue to be viable.
Antibiotic-Treated, IPP-Rescued Parasites Lose Protein
Import Function
A critical function of the apicoplast, required for the
maintenance of its proteome, is the import of nuclear-encoded
proteins into the organelle. A bipartite N-terminal sequence
consisting of a signal sequence and a transit peptide is required to
target proteins to the organelle [8]. Upon import into the
apicoplast, the transit peptide is cleaved to produce a mature
protein [8]. Protein processing is therefore a marker of successful
protein import into the apicoplast. We used a transgenic D10
strain expressing GFP fused to an N-terminal apicoplast targeting
sequence (ACPL-GFP) to assess apicoplast protein processing
during the course of antibiotic treatment and IPP rescue [8]. The
33 kDa full-length GFP was cleaved to produce a predominant
30 kDa mature protein in untreated parasites (Figure 3A).
Parasites treated with doxycycline only began to lose protein
processing function during the 2nd cycle as seen in the increased
accumulation of full-length protein at 96 h but do not survive
beyond this cycle (Figure 3B). When doxycycline treatment was
rescued with IPP, surviving parasites showed successive loss of
protein processing with each treatment cycle such that only
preprocessed GFP was detectable at 144 h, the start of the 4th
cycle (Figure 3C). A smaller, previously described degradation
band also became apparent in the rescued parasites [8]. The
absence of protein processing activity indicates a loss of the critical
protein import function of the apicoplast in these rescued
parasites.
Figure 2. Rescue of antibiotic delayed death and apicoplast
genome loss. (A) Survival of parasites over 4 life cycles treated with (1)
doxycyline only, (2) doxycycline+IPP, or (3) doxycycline+IPP for three
cycles followed by removal of both. Parasitemia is normalized to that of
an untreated control. (B) Apicoplast:nuclear and (C) mitochondria:-
nuclear genome ratio of doxycycline only and doxycycline+IPP treated
parasites over the same time course. Genome ratios are normalized to
an untreated control. Data from three separate passages are shown.
doi:10.1371/journal.pbio.1001138.g002
Chemical Rescue of Apicoplast-Minus P. falciparum
PLoS Biology | www.plosbiology.org 4 August 2011 | Volume 9 | Issue 8 | e1001138
Antibiotic-Treated, IPP-Rescued Parasites Lack an
Apicoplast
The final outcome of antibiotic treatment is a failure of
apicoplast replication and segregation during cell division,
resulting in loss of the organelle and death [9]. The loss of the
genome and protein import function strongly suggests that
parasites that survive antibiotic treatment are in fact apicoplast-
minus. Localization of GFP in the D10 ACPL-GFP strain was used
to visualize the apicoplast. As expected, GFP localizes to a discrete
structure in the parasite in untreated cells (Figure 4 and Video S1).
In contrast, in parasites that have been rescued from antibiotic
death, GFP loses this discrete apicoplast localization and becomes
diffuse (Figure 4). Confocal images show that numerous foci of
GFP are scattered throughout the cytoplasm (Figure 4 and Video
S2). The largest foci measure .200 nm, so these collections of
GFP are less likely to be cytoplasmic protein aggregates but instead
may represent vesicles containing protein. Combined with the
absence of the apicoplast genome and protein import function, the
loss of GFP localization indicates the absence of the apicoplast
itself to which it is normally targeted.
Discussion
Until now, the mystery of apicoplast function has been a critical
gap in our understanding of malaria pathogenesis. Our findings
demonstrate that the production of isoprenoid precursors is the
only essential function of the apicoplast during asexual blood-stage
P. falciparum growth (Figure 5). This surprising revelation has
several important implications and invites a host of new questions.
Because isoprenoid precursors are building blocks to synthesize
cellular isoprenoid products with diverse functions, their key role
now gives added urgency to the elucidation of these products and
their downstream functions. At least one essential prenylated
product is ubiquinone, a component of the mitochondrial electron
transport chain. There are certainly other essential, as-yet-
unidentified isoprenoid products since transgenic parasites which
express yeast dihydroorotic acid dehydrogenase and no longer
require their electron transport chain are still susceptible to
fosmidomycin and antibiotics and could be rescued with IPP
supplementation (unpublished data) [36]. Possible isoprenoid
products include dolichols involved in protein N-glycosylation
which have been detected in Plasmodium and prenylated proteins,
such as Rab homologs required for vesicular trafficking and a
recently identified tyrosine phosphatase [37–41].
The current findings also imply that several annotated
apicoplast pathways are in fact non-essential. Amongst both
identified pathways and the 70% of apicoplast gene products with
unknown function, only isoprenoid precursor biosynthesis and any
pathways supporting this function in blood-stage parasites
(including those required for organelle maintenance and replica-
tion) are essential and therefore viable apicoplast drug targets [20].
Assertions that type II fatty acid and, by implication, acetyl-CoA
biosynthesis were essential apicoplast functions during blood-stage
growth have already been disproven [23,24,42]. A parasite-
derived pathway for heme biosynthesis contains steps that occur in
the apicoplast, mitochondria, and cytosol. Our results strongly
imply that blood-stage parasites do not depend on de novo heme
biosynthesis using this pathway but instead rely on an extrinsic de
novo pathway utilizing imported host enzymes or salvage of heme
from the host by an unidentified mechanism [43,44]. Still other
pathways such as Fe-S cluster biosynthesis supply cofactors for
enzymes within the organelle but are not exported outside the
organelle. These pathways become ‘‘non-essential’’ when the need
for organelle maintenance is removed.
The complexity of the organelle and the simplicity of its blood-
stage function pose an obvious contradiction. Approximately 5%–
10% of the Plasmodium genome is predicted to encode apicoplast-
targeted gene products (although the localization and/or function
of the majority of these gene products have not been validated)
[20]. In order to import these proteins into the apicoplast,
parasites utilize a dedicated protein trafficking pathway [7,8]. In
addition, the organelle undergoes complex morphological devel-
opment during blood stage growth, requiring cellular machinery
to faithfully replicate and segregate the organelle at every cell
division [10]. Why are such huge resources consumed to maintain
a single essential function? First, while the function of the
apicoplast is limited during the blood stage, the need for more
extensive organelle function during other developmental stages
may dictate its maintenance in intraerythrocytic parasites as the
organelle cannot be generated de novo. Fatty acid biosynthesis, for
example, is an essential apicoplast function in liver stage parasites
[23,24]. Second, Plasmodium may have been evolutionarily trapped
in its bondage to the apicoplast. Having acquired the plastid early
in its evolution, it may have been unable to dispense of it even after
adopting an increasingly parasitic lifestyle due to the transfer of
even a few essential functions to the organelle. In any case, this
imbalance emphasizes the value of targeting housekeeping
pathways involved in organelle maintenance and replication to
interfere with its function.
An important consideration is whether our findings accurately
reflect in vivo growth requirements of parasites during infection.
Specifically, are there essential metabolites supplemented in
culture which could not be acquired during in vivo growth and
instead must be biosynthesized by the apicoplast? While
parasitized RBCs during infection use human plasma as a source
of extracellular nutrients, our cultures were grown in RPMI
medium 1640 supplemented with purified serum substitute,
Albumax. We found that Albumax could be replaced with 10%
Figure 3. Loss of protein processing of apicoplast-targeted proteins in antibiotic-treated, rescued parasites. Immunoblot using anti-
GFP shows a time course of apicoplast-dependent protein processing of apicoplast-targeted GFP in (A) untreated, (B) doxycycline-treated, and (C)
doxycycline+IPP treated parasites.
doi:10.1371/journal.pbio.1001138.g003
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human serum with no effect on the survival of apicoplast-minus
parasites in the presence of IPP (Figure S5). RPMI medium
contains salts, 20 amino acids, 11 vitamins, 4 other organic
molecules, and glucose. The acquisition and biosynthesis of these
nutrients by blood-stage Plasmodium and their essentiality for
intraerythrocytic growth based on available evidence is shown in
Table S1. In general, blood-stage Plasmodium biosynthesizes very
limited amounts of just 3 amino acids and is dependent on amino
acids from either (1) hemoglobin degradation or (2) acquisition
from patient plasma through newly established permeation
pathways in the infected red cell [45–47]. Similarly, current
knowledge of Plasmodium metabolism also suggests that the
remaining organic metabolites found in RPMI medium are
biosynthesized by non-apicoplast pathways or can be acquired
from the host red cell or patient plasma [46,48–50]. Consequently,
we believe that our findings can be extrapolated to in vivo
requirements for the apicoplast to support parasite growth and
development. At the very least, our results define a very minimal
set of potential metabolites (IPP and components found in RPMI
1640 medium) that could be biosynthesized in the apicoplast. We
cannot, however, rule out additional apicoplast functions (other
than those required for growth) that would not be revealed in our
blood culture system, such as functions required for immune
evasion.
Several aspects of the chemical rescue with isoprenoid
precursors are notable. During chemical rescue, exogenous IPP
could enter the parasite through permeation pathways established
in the parasitized erythrocyte or other uncharacterized membrane
transporters [46,51]. The RBC is largely metabolically inactive
and unlikely to have significant ongoing isoprenoid precursor
biosynthesis via the host mevalonate pathway or stores of these
metabolites [52]. It is also unlikely that these high-energy
pyrophosphorylated molecules would accumulate to appreciable
levels in plasma (200 mM was required for rescue in our
experiments). Consistent with this notion, IPP was not present in
the Serum Metabolome Database (SMDB), which contains 4,229
detectable metabolites [53]. Therefore, acquisition of isoprenoid
precursors in vivo by salvage of IPP from infected blood is
Figure 4. Loss of localization of apicoplast-targeted proteins in antibiotic-treated, rescued parasites. Widefield epifluorescence
microscopy for apicoplast (ACPL-GFP) and nucleus (Hoescht 33342) comparing ring, trophozoite, and schizont in untreated parasites and
chloramphenicol+IPP treated parasites. To right, confocal 3-D reconstruction of untreated parasites and chloramphenicol+IPP treated early
trophozoite stage parasites.
doi:10.1371/journal.pbio.1001138.g004
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improbable. Once in the parasite, exogenous IPP may fulfill its
function in the cytoplasm with or without uptake into the
apicoplast [54].
Although both IPP and DMAPP are required to synthesize
isoprenoid products, supplementation with IPP alone is sufficient
to fulfill endogenonous isoprenoid precursor biosynthesis, implying
the presence of an IPP isomerase in the cytoplasm that converts
IPP to DMAPP. This activity may be important in establishing the
optimal cellular ratio of IPP to DMAPP, as toxicity was noted with
increasing DMAPP concentrations in our experiments. A putative
IPP isomerase has been identified in the Plasmodium genome [55].
A recent report suggested that geranylgeraniol, the alcohol analog
of a C20 prenyl chain, could rescue fosmidomycin inhibition [56].
We were unable to rescue fosmidomycin inhibition with alcohol
analogs of IPP and DMAPP, indicating either poor cellular
penetration of the alcohols or the absence of a kinase to convert
the alcohol analogs to the pyrophosphorylated and active
metabolites (Figure S1). Even with conversion of geranylgeraniol
to geranylgeranyl pyrophosphate in the cell, it would seem that a
C5 building block, such as IPP, would almost certainly be required
to extend the supplemented C20 unit for construction of polyprenyl
chains, such as that found in ubiquinone, and to construct smaller
prenyl chains, such as for protein farnesylation. The reported
rescue with geranylgeraniol was performed at 1.5 mM fosmido-
mycin, which is above the concentration required for 50% growth
inhibition but may be below that required for adequate inhibition
of the biosynthetic pathway (since phenotypic growth inhibition
can be apparent even at low levels of inhibition of the biosynthetic
pathway) [56]. Therefore, the reported results may be complicated
by ongoing biosynthesis of IPP and DMAPP contributing to the
precursor pool. Consistent with this, neither farnesol nor
geranylgeraniol was able to rescue fosmidomycin concentrations
.10 mM, and both showed dose-related parasite toxicity (Figure
S6). In contrast, we were able to demonstrate IPP rescue at
fosmidomycin concentrations exceeding 100 mM, well above its
EC90 for growth inhibition.
The consequences of apicoplast loss following antibiotic
treatment and IPP rescue are no less intriguing. In the parasites
that survive antibiotic treatment by chemical rescue, the organelle
is irreversibly lost when it fails to segregate to daughter cells [9]. In
these apicoplast-minus parasites, apicoplast gene products encoded
in the nucleus may continue to be transcribed and translated.
These products may properly shuttle into the secretory pathway
but cannot be diverted to the organelle [8]. Based on the
Figure 5. Model of apicoplast function. (Top) The essential function of the apicoplast is the production of isoprenoid precursors, IPP and DMAPP,
which are exported into the cytoplasm and used to synthesize small molecule isoprenoids and prenylated proteins. Parasites that are unable to
synthesize isoprenoid precursors either due to inhibition of the biosynthetic pathway by fosmidomycin or loss of the apicoplast following
doxycycline inhibition can be chemically rescued by addition of exogenous IPP (red). The exogenous IPP enters the host cell through unknown
membrane transporters and fulfills the missing biosynthetic function. (Bottom) Reaction scheme for MEP pathway biosynthesis of IPP and DMAPP
with the enzymatic step inhibited by fosmidomycin indicated.
doi:10.1371/journal.pbio.1001138.g005
Chemical Rescue of Apicoplast-Minus P. falciparum
PLoS Biology | www.plosbiology.org 7 August 2011 | Volume 9 | Issue 8 | e1001138
microscopy results, we hypothesize that proteins may be packaged
into transport vesicles bound for the organelle but are unable to
localize to the missing structure and therefore accumulate in the
cytoplasm appearing as numerous foci. While we cannot rule out
the presence of structural remnants of the apicoplast, the observed
foci are unlikely to support apicoplast functions. Apicoplast-
targeted proteins may require both cleavage of the long basic
transit peptide and chaperones in the lumen of the apicoplast for
proper folding. We observed that cleavage of the transit peptide
from targeted proteins, a critical apicoplast function, does not
occur in rescued parasites (Figure 3C).
The close physical and functional relationship between the
apicoplast and the mitochondria raises the possibility that loss of
the apicoplast might affect the ability of the mitochondria to
replicate and divide. We were able to detect the mitochondrial
genome by qPCR for the cytB3 gene and observe labeling of the
mitochondria with Mitotracker by fluorescence microscopy in
apicoplast-minus parasites (Figure 2C; unpublished data). Despite
the loss of the apicoplast, these parasites do appear to contain
mitochondria.
While the survival of apicoplast-minus P. falciparum invokes a
slew of intriguing questions, these same parasites will be a powerful
and indispensable tool for further dissection of apicoplast biology.
Apicoplast-minus P. falciparum strains generated in this study can
be used to assess organelle requirement during gametocytogenesis
and mosquito stage development. These strains also provide novel
avenues to identify isoprenoid products, generate conditional
mutants of essential genes involved in apicoplast maintenance and
replication, conduct metabolomic or proteomic profiling, and
study protein trafficking to the organelle.
With regard to drug development, our chemical rescue strategy
also addresses the critical deficiency of current cell growth screening
assays, namely lack of knowledge of the drug target. Candidate drug
hits detected in phenotypic assays can be screened for chemical
rescue of the growth inhibition. The reversal of growth inhibition by
IPP supplementation specifically identifies inhibitors that target
pathways involved in MEP pathway function, replication, or
maintenance of the apicoplast, providing a pathway-specific drug
screen to aid in discovery of new classes of anti-malarials. The ability
to chemically complement the cell death phenotype will prevent
false leads from off-target effects, like that seen with triclosan and its
misconstrued effect on type II fatty acid biosynthesis [22].
Finally, the apicoplast-minus strains dependent on IPP for
continued growth are a unique and ideal candidate for an
attenuated blood-stage vaccine [57,58]. Unlike irradiated or drug-
treated whole parasite vaccines, apicoplast-minus parasites would
continue to develop in blood at most one cycle, including a single
erythrocyte rupture and reinvasion, thereby stimulating a stronger
immune response. However, judging by the effects of IPP
withdrawal in culture, they would be unable to develop further
in the absence of exogenous IPP (Figure 2A). Lending support to
this notion, a similar ‘‘limited survival’’ strategy targeting the
apicoplast in liver-stage parasites has proven effective as a liver-
stage vaccine candidate [59]. A significant advantage of our
approach is that attenuation is achieved chemically and does not
require difficult or costly genetic manipulation (as is the case with
genetically modified vaccine strains), thereby allowing for the
possibility of incorporating circulating field strains of Plasmodium in
a vaccine formulation [60]. There would also be very little risk of
reversion as it would be extremely difficult to reacquire apicoplast
function by mutation.
In summary, we believe that the current study ushers in a new
era in the investigation of the apicoplast in Plasmodium with exciting
opportunities to counteract the malarial scourge on human lives.
Materials and Methods
P. falciparum Cultures
Plasmodium falciparum W2 (MRA-157), D10 (MRA-201), and
D10 ACPL-GFP (MRA-568) were obtained from MR4. Parasites
were grown in human erythrocytes (2% hematocrit) in RPMI 1640
media supplemented with 0.25% Albumax II (GIBCO Life
Technologies), 2 g/L sodium bicarbonate, 0.1 mM hypoxanthine,
25 mM HEPES (pH 7.4), and 50 mg/L gentamycin, at 37uC, 5%
O2, and 6% CO2. For D10 ACPL-GFP, the media was also
supplemented with 100 nM pyrimethamine (Sigma).
For passage of antibiotic-treated, IPP-rescued parasites, the
media was supplemented with 1.5–2 mM doxycycline or 50 mM
chloramphenicol. 48 h after initiation of antibiotic treatment,
rescued strains were supplemented with 200 mM IPP (Isoprenoids
LC) for continuous passage. For comparison of growth between
different treatment conditions, cultures were carried simultaneous-
ly and handled identically with respect to media changes and
addition of blood cells.
Drug Susceptibility Assays
Growth assays were performed in 96-well plates containing
serial dilution of drugs in duplicate or triplicate. Media was
supplemented with IPP or DMAPP as indicated. To determine the
EC50 of fosmidomycin (Invitrogen), growth was initiated with ring-
stage parasites (synchronized with 2.5% sorbitol treatment 48 h
prior) at 1% parasitemia (0.5%–2% hematocrit). Plates were
incubated for 72 h. To determine the EC50 of antibiotics at 48 h,
growth was initiated at 1% parasitemia and incubated for 48 h. To
determine the EC50 of antibiotics at 96 h and observe the delayed
death phenotype, cultures were initiated at 0.2% parasitemia, 75%
of the media was exchanged at 48 h, and plates were incubated for
an additional 48 h (total 96 h). For all assays, growth was
terminated by fixation with 1% formaldehyde and parasitized
cells were stained with 50 nM YOYO-1 (Invitrogen). Parasitemia
was determined by flow cytometry. Data were analyzed by FlowJo,
and EC50 curves plotted by GraphPad Prism.
Quantitative Real-Time PCR
Parasites from 200 mL of culture were isolated by saponin lysis
followed by PBS wash to remove extracellular DNA. DNA was
purified using QiaAMP blood kits (Qiagen). Primers were designed to
target genes found on each organelle or nuclear genome: tufA
(apicoplast) 59-GATATTGATTCAGCTCCAGAAGAAA-39 / 59-
ATATCCATTTGTGTGGCTCCTATAA-39, cytb3 (mitochondria)
59-AGATACATGCACGCAACAGG-39 / 59-TCATTTGACCC-
CATGGTAAGA-39, and CHT1 (nuclear) 59-TGTTTCCTTCA-
ACCCCTTTT-39 / 59-TGTTTCCTTCAACCCCTTTT-39. Re-
actions contained template DNA, 0.15 mM of each primer, and
0.756 LightCycler 480 SYBR Green I Master mix (Roche). PCR
reactions were performed at 56uC primer annealing and 65uC
template extension for 35 cycles on a Lightcycler 6500 (Roche).
Relative quantification of target genes was determined using the
method of Pfaffl [61]. For each time point, the organelle:nuclear
genome ratio of the antibiotic-treated control or antibiotic-treated,
IPP-rescued experiment was calculated relative to that of an
untreated control collected at the same time.
Immunoblot
Ring-stage D10 ACPL-GFP parasites from 1 mL of culture were
isolated by saponin lysis, washed with PBS, and resuspended in
16NuPAGE LDS sample buffer (Invitrogen). Proteins were
separated by electrophoresis on 12% Bis-Tris gel (Invitrogen)
and transferred to nitrocellulose membrane. After blocking,
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membranes were probed with 1:1,000 polyclonal rabbit anti-GFP
(Clontech) antibody and 1:15,000 Alexa Fluor 810-conjugated
anti-rabbit IgG secondary antibody (Invitrogen). Fluorescent
antibody-bound proteins were detected with Odyssey Imager at
800 nm (LiCor Biosciences).
Fluorescence Microscopy
Untreated and antibiotic treated/IPP rescued D10 ACPL-GFP
parasites were incubated in 2 mg/mL Hoescht 33342 stain for
30 min at 37uC. Cells in culture media were settled onto 35 mm
glass-bottom petri dishes (MakTek) coated with 1% polyethyleni-
mine (Sigma). Widefield epifluorescence live cell images were
obtained on a Nikon Eclipse Ti-E equipped with a Coolsnap HQ2
camera (Photometrics) using a 1006/1.4 oil immersion objective.
Confocal live cell images were obtained on an A1 confocal
mounted on a Nikon Eclipse Ti-E using a 606/1.4 oil immersion
objective. Images were analyzed by NIS-Elements software
(Nikon).
Supporting Information
Figure S1 Fosmidomycin rescue with methylbutenols. Chemical
rescue of fosmidomycin inhibition in media supplemented with 0–
2 mM 3-methyl-3-butenol (IPP alcohol analog) or 0–2.25 mM 3-
and 2-methyl-3-butenol (IPP and DMAPP alcohol analogs).
(TIFF)
Figure S2 IPP rescue of chloroquine inhibition. Chemical rescue
of chloroquine inhibition (0–20 mM) in media supplemented with
200 mM IPP.
(TIFF)
Figure S3 Rescue of antibiotic delayed death in strain D10.
Survival of D10 parasites over a time course of treatment with
chloramphenicol only, chloramphenicol+IPP, and chlorampheni-
col+IPP for 3 cycles followed by removal of both. Parasitemia is
normalized to that of an untreated control. Data from a single
experiment are shown.
(TIFF)
Figure S4 Rescue of antibiotic delayed death and apicoplast
genome loss with chloramphenicol treatment in strain W2. (A)
Survival of W2 parasites over a time course of treatment with
chloramphenicol only, chloramphenicol+IPP, and chlorampheni-
col+IPP for 3 cycles followed by removal of both. Parasitemia is
normalized to that of an untreated control. (B) Apicoplast:nuclear
and (C) mitochondria:nuclear genome ratio of chloramphenicol
only and chloramphenicol+IPP treated parasites over the same
time course. Genome ratios are normalized to an untreated
control. Data from experiments carried out in triplicate are shown.
(TIFF)
Figure S5 Survival of antibiotic-treated, IPP-rescued parasites in
media supplemented with 10% human serum. Untreated and
antibiotic-treated, IPP-rescued W2 parasites were initially grown
in media containing Albumax. Each culture was washed and then
split into two cultures, which were resuspended in RPMI media
supplemented with either 0.25% Albumax or 10% human serum
at a starting parasitemia of 1%–2%. Parasitemia was determined
by 200-cell counts of Giemsa-stained blood smears. Growth of the
10% serum culture is shown relative to that of the Albumax
culture for both untreated and rescued strains. Data from a single
experiment are shown.
(TIFF)
Figure S6 Fosmidomycin rescue with farnesol and geranylger-
aniol. Chemical rescue of fosmidomycin inhibition in media
supplemented with 0–500 mM farnesol or geranylgeraniol.
(TIFF)
Table S1 Components of RPMI Medium 1640 (Invitrogen),
their plasma concentration, and evidence for their acquisition or
biosynthesis by blood-stage Plasmodium.
(DOC)
Video S1 Movie showing 360u rotation of confocal images of
untreated ACPL-GFP parasites shown in Figure 4.
(M4V)
Video S2 Movie showing 360u rotation of confocal images of
chloramphenicol+IPP treated ACPL-GFP parasites shown in
Figure 4.
(M4V)
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